Transgene - INITIATION - Best-in-Class Cancer Tech (TP EUR 3.20, 95% Upside)
Transgene is a French biotech company that develops targeted & personalised cancer vaccines as well as oncolytic viruses through their myvac and Invir.IO platforms respectively. TG4001 is an earlier generation asset which treats HPV+ cancer patients and has published promising P1/2 data; a pivotal trial is expected to be initiated as soon as Q2 2021. We expect readouts from assets from both platforms by H221, which will advance the investment thesis, but even before that, we value the company at €3.20/share, which includes €160m of future capitalised R&D and G&A costs.For access to the full note, please contact Naresh Chouhan
Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.